The antiviral, Daclatasvir, downregulates Tribbles 2 pseudokinase and reverses enzalutamide resistance in prostate cancer

被引：0
|
作者：
Monga, Jitender
Guddeti, Rohith
Rogers, Craig
Gadgeel, Shirish
Chitale, Dhananjay
Ghosh, Jagadananda
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4751
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells
    Foulkes, Daniel M.
    Byrne, Dominic P.
    Yeung, Wayland
    Shrestha, Safal
    Bailey, Fiona P.
    Ferries, Samantha
    Eyers, Claire E.
    Keeshan, Karen
    Wells, Carrow
    Drewry, David H.
    Zuercher, William J.
    Kannan, Natarajan
    Eyers, Patrick A.
    SCIENCE SIGNALING, 2018, 11 (549)
  • [42] Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells
    Wang, Yu
    Dehigaspitiya, Dilani C.
    Levine, Paul M.
    Profit, Adam A.
    Haugbro, Michael
    Imberg-Kazdan, Keren
    Logan, Susan K.
    Kirshenbaum, Kent
    Garabedian, Michael J.
    CANCER RESEARCH, 2016, 76 (17) : 5124 - 5132
  • [43] Proteomic identification of therapeutics targets for Enzalutamide resistance in Castration Resistant Prostate Cancer
    Velot, Lauriane
    Levesque, Dominique
    Boisvert, Francois-Michel
    Bisson, Nicolas
    Pouliot, Frederic
    CANCER RESEARCH, 2017, 77
  • [44] Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide
    Greene, John
    Baird, Anne-Marie
    Casey, Orla
    Brady, Lauren
    Blackshields, Gordon
    Lim, Marvin
    O'Brien, Odharnaith
    Gray, Steven G.
    McDermott, Raymond
    Finn, Stephen P.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [45] High Mobility Group AT-hook 2: A Biomarker Associated with Resistance to Enzalutamide in Prostate Cancer Cells
    Liadi, Yusuf Mansur
    Campbell, Taaliah
    Hwang, Bor-Jang
    Elliott, Bethtrice
    Odero-Marah, Valerie
    CANCERS, 2024, 16 (15)
  • [46] Identifying serum biomarkers for predicting the resistance of enzalutamide or abiraterone in prostate cancer patients
    Chuu, Chihpin
    Lin, Tzuping
    Huo, Chieh
    CANCER SCIENCE, 2024, 115 : 329 - 329
  • [47] Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2015, 193 (02): : 538 - 538
  • [48] Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Anand, Aseem Undvall
    Bjartell, Anders
    EUROPEAN UROLOGY, 2015, 67 (02) : 349 - 350
  • [49] Using functional and chemical genomics to identify mechanisms of Enzalutamide resistance in prostate cancer
    Jeganathan, Sujeeve
    Zoubeidi, Amina
    Gleave, Martin
    Wouters, Brad G.
    Joshua, Anthony M.
    CANCER RESEARCH, 2015, 75
  • [50] Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
    Zhu, Zhe
    Xuan, Wenjing
    Wang, Chaohui
    Li, Chancan
    FRONTIERS IN ONCOLOGY, 2024, 14
12345